BlackRock’s Bioverativ Inc. Common Stock BIVV Stock Holding History

BlackRock’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,845,635	Closed	-$585M	–	5081
2017 Q4	$585M	Buy	10,845,635 +1,567,638	+17%	+$85.8M	0.03%	620
2017 Q3	$529M	Sell	9,277,997 -109,411	-1%	-$6.41M	0.03%	625
2017 Q2	$565M	Buy	9,387,408 +600,836	+7%	+$34.2M	0.03%	590
2017 Q1	$479M	Buy	+8,786,572	New	+$433M	0.03%	673

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

BlackRock's BIVV Position: Q1 2018 in Review

BlackRock sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 10,845,635 shares — an estimated $585M sold.

BlackRock first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $585M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

BlackRock reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
BlackRock sold 10,845,635 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $585M.
BlackRock first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
BlackRock's Bioverativ Inc. Common Stock position peaked at $585M in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on BlackRock's 13F filing for Q1 2018, filed 9 May 2018.